Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor…
Primary Biliary Cholangitis – Unmet Need – Unmet Need – Primary Biliary Cholangitis (US/EU)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and destruction of the interlobular bile ducts, followed by cholestasis,…
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease | US/EU
The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, LABA/LAMA/ICSs, and, most recently, the…
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Breast Cancer – Unmet Need – Unmet Need – Metastatic Triple-Negative Breast Cancer (US/EU)
The treatment of metastatic triple-negative breast cancer is rapidly evolving with new combination therapies and biomarker-driven approaches. Immunotherapies such as Keytruda (Merck & Co.) have…
